ClinicalTrials.gg
Not yet recruitingNCT07864584Updated Oct 8, 2026

Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer

A Phase 1/2 interventional study of NHT102 and DryNeb in NSCLC (Advanced Non-small Cell Lung Cancer), sponsored by Nob Hill Therapeutics, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Nob Hill Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Updated Oct 8, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing azacitidine in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 1 under way, none of them phase 3. Azacitidine · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 12
100 · median 29
Started
2027
the only one that year
Phase 1/2
2 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Nob Hill Therapeutics, Inc.

Among the 13 studies testing azacitidine in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 1/2, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 13 studies testing azacitidine in Carcinoma, Non-Small-Cell Lung is open now, in 1 country.

By country, each count listing its studies:

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing azacitidine in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

There are 3 parts to this clinical trial. The goal of this clinical trial (NHT102-001) is to learn how safe NHT102 is, what dose works best, and whether it can help treat advanced non-small cell lung cancer (NSCLC) that has come back or remained after earlier treatment and is still confined to the lung / chest region by providing targeted inhaled treatment directly to the lungs. NHT102 is a dry powder that participants breathe in through a mouthpiece using an investigational inhalation device. Doses are given at the study site by trained staff, not at home. NHT102 is taken on days 1-5 and days 15-19 of a 28-day cycle.

The main questions this clinical trial aims to answer are:

Part 1 (Dose Escalation): To look at up to five different increasing dose levels of NHT102 to see if they are safe and well-tolerated and if the body absorbs the medicine from the lungs. To see if up to two dose levels studied are not only safe, but also make the cancer slow its growth or lessen its spread. And to see the highest dose that is tolerated by participants.

Part 2 (Dose Optimization): To further study at up to two dose levels from Part 1 and randomly assign participants in equal numbers to one of them to learn more about NHT102's safety, how well the drug is absorbed from the lungs and how well each dose level works against the NSCLC after at least 4 months. Then identify which of the two doses is chosen for further study.

Part 3 (Dose Expansion): Take the dose chosen in from Part 2 and study it in more patients to continue look at the drug safety, how much of it is absorbed into the body from the lungs and if it works to stop or reduce the spread of NSCLC.

Participants will:

  • Take NHT102 at the study site daily on days 1-5 days and days 15-19 during a 28-day cycle for as long as it is helping them and they can tolerate it. Treatment stops if the cancer worsens, if side effects become too difficult to manage, or if the participant or their doctor decides to stop.
  • Tell doctors and staff about all medications they are taking, any issues with their study medication and all side effects they may be having whether they are taking the medication that day or not.
  • Return for a safety visit about 30 days after their last dose, then receive phone calls about 3 months and 6 months later to check on their health.
Read the detailed description

This is an open label, multi-center Phase 1/2 study of NHT102, 5-Azacytidine Mircronised, Dry Powder Formulation Delivered by a Novel Inhalation Delivery System (device constituent product [DCP]). The study will enroll patients with advanced NSCLC limited to the lung and thoracic region. The study consists of three sequential parts:

Part 1 (Dose Escalation): Approximately five dose levels of NHT102 will be evaluated using a standard 3+3 design to determine dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD). Patients receive NHT102 once daily on Days 1-5 and Days 15-19 of each 28 day cycle. A Safety Review Committee (SRC) will review safety data after each cohort completes the DLT evaluation period.

Part 2 (Dose Optimization): At least two dose levels selected from Part 1 will be evaluated using Simon's two stage design. Each dose level will enroll up to 25 evaluable patients to assess anti-tumor activity, safety, pharmacokinetics (PK), pharmacodynamics, and exploratory biomarkers.

Part 3 (Dose Expansion): The recommended Phase 2 dose (RP2D) selected from Part 2 will be further evaluated to characterize safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity.

Patients will continue treatment until disease progression, unacceptable toxicity, withdrawal of consent, investigator decision, or study termination. Follow up includes safety assessment at 30 days after end of treatment and 6 month survival follow up.

03

Conditions studied

  • NSCLC (Advanced Non-small Cell Lung Cancer)

Keywords

  • Lung Cancer
  • Non-small cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Able to provide
  • Able to perform acceptable and reproducible spirometry per ATS criteria
  • Able to perform inhalation maneuver
  • or cytologically confirmed NSCLC (squamous, adenocarcinoma, or large cell undifferentiated)
  • Stage I-III NSCLC per AJCC 9th edition with recurrent or persistent thoracic confined disease
  • Prior therapy with curative intent completed
  • Actionable genomic alterations must have been treated or offered appropriate targeted therapy
  • Not eligible for additional curative therapy
  • At least one measurable lung lesion per v1.1 (measurable extra-pulmonary thoracic lesions do not qualify unless a measurable lung lesion is also present)
  • performance status ≤2
  • ≥12 weeks
  • Adequate hematologic, renal, hepatic, and cardiovascular function
  • Washout from prior therapy ≥30 days or ≥5 half lives
  • Adequate pulmonary reserve: ≥50% predicted, FEV1/FVC ≥45%, and DLCO ≥50% predicted
  • No growth factor support, transfusions, or albumin within 14 days prior to first dose
  • Resolution of adverse effects of prior therapy to Grade ≤1 (except fatigue, alopecia, and peripheral neuropathy)
  • requirements for and fertile men
  • Agreement to refrain from smoking or inhaled substances during treatment

Exclusion criteria

Exclusion Criteria:

  • Systemic beyond the lung, thoracic lymph nodes, or mediastinum region
  • Anticancer therapy within 30 days or 5 half-lives, or current immunomodulator requirement
  • to study drug or device components
  • Concurrent anticancer therapy or immunomodulators
  • Systemic or inhaled (exceptions apply)
  • Active smokers within past 6 months
  • Severe airway disease (criteria defined)
  • Radiation therapy within 6 months
  • to study procedures
  • Other except specified low risk types
  • Major surgery within 4 weeks
  • cardiovascular disease
  • Uncontrolled medical conditions
  • Active infection requiring IV therapy
  • within 2 weeks of Cycle 1 Day 1
  • Bleeding disorder unrelated to cancer
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Participants receive NHT102 via inhalation once daily on Days 1-5 and Days 15-19 of each 28 day cycle. Up to five dose levels (7 mg to 42 mg target lung dose \[TLD\] per treatment day) are evaluated using a standard 3+3 design to determine dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD). Additional intermediate dose level cohorts may be added at the recommendation of the Safety Review Committee (SRC). Interventions: NHT102 (5-AZA dry powder for inhalation) DryNeb Device

    Drug: NHT102 · Device: DryNeb

  • Experimental
    Dose Optimization

    Participants are randomized 1:1 to one of two dose levels selected from Part 1. Each dose level is evaluated using Simon Two Stage design to assess anti-tumor activity, safety, pharmacokinetics, pharmacodynamics, and exploratory biomarkers. Up to approximately 25 evaluable patients may be enrolled per dose level.

    Drug: NHT102 · Device: DryNeb

  • Experimental
    Dose Expansion

    Participants receive NHT102 at the recommended Phase 2 dose (RP2D) determined from Part 2. This part further evaluates safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity.

    Drug: NHT102 · Device: DryNeb

Interventions

  • DrugNHT102

    NHT102 is an investigational drug product, 5-Azacytidine dry powder for oral inhalation. NHT102 is administered once daily via inhalation using a novel investigational inhalation delivery system. Dosing occurs on Days 1-5 and Days 15-19 of each 28-day cycle. Multiple dose levels (7 mg to 42 mg target lung dose per treatment day) are evaluated in Part 1, selected dose levels in Part 2, and the recommended Phase 2 dose (RP2D) in Part 3.

    Also known as: 5-AZA, 5-Azacytidine dry powder, NHT102-5-AZA, Azacitidine

  • DeviceDryNeb

    The DryNeb is a novel investigational inhalation delivery system that delivers micronized dry powder to the lungs.

    Also known as: Clinical Benchtop DryNeb, Novel Inhalation Delivery System

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events (AEs)

    Treatment emergent adverse events, serious adverse events, and clinically significant laboratory or vital sign abnormalities assessed using CTCAE v6.0 (Part I).

    Time frame: From first dose through 30 days after the last dose.

  2. Incidence of dose-limiting toxicities (DLT)-Part I

    Number of participants experiencing DLTs during the DLT evaluation period, defined per protocol.

    Time frame: 28-day DLT evaluation period (Cycle 1)

  3. Overall Response Rate (ORR)-Parts 2 and 3.

    Proportion of participants achieving complete or partial response per RECIST v1.1.

    Time frame: From first dose until first documented disease progression, date of death or patient withdrawal from the study for any reason, assessed up to six months.

  4. Progression Free Survival (PFS)-Parts 2 and 3.

    Time from first dose to disease progression or death.

    Time frame: From first dose until first documented disease progression, date of death or patient withdrawal from the study for any reason, assessed up to six months.

  5. Overall Survival (OS)-Parts 2 and 3.

    Time from first dose to death.

    Time frame: From first dose until first documented disease progression, date of death or patient withdrawal from the study for any reason, assessed up to six months.

  6. Duration of Response (DOR)-Parts 2 and 3.

    Time from first observation of response to progression or death.

    Time frame: From first documented response to date of first documented disease progression, date of death or patient withdrawal from the study for any reason, assessed up to six months.

Secondary outcomes

  1. Pharmacokinetic Parameters of NHT102-Parts 1, 2, and 3.

    To determine the PK parameter for the peak plasma concentration (Cmax).

    Time frame: At the end of Cycle 1. (Each cycle is 28 days)

  2. Incidence and Severity of Adverse Events (AEs)-Parts 2 and 3.

    TEAEs, SAEs, and clinically significant abnormalities assessed using CTCAE v6.0.

    Time frame: From first dose through 30 days after the last dose.

  3. Percent Change in DNA Methylation-Parts 2 and 3.

    Percent change in global DNA methylation in tumor and/or bronchial epithelium compared with pre treatment.

    Time frame: Baseline to post-treatment (estimated to be minimum of 7 months)

  4. PK parameters of NHT102. Parts 1, 2, and 3.

    Area under the curve (AUC) plasma concentration versus time curve.

    Time frame: At the end of Cycle 1. (Each cycle is 28 days)

  5. PK Parameters of NHT102. Parts 1, 2, and 3.

    Time to maximum plasma concentration (Tmax)

    Time frame: At the end of cycle 1. (Each cycle is 28 days)

  6. PK parameters of NHT102. Parts 1, 2 and 3.

    Estimated time to reduce the plasma concentration by exactly one half (T1/2)

    Time frame: At the end of Cycle 1. (Each Cycle is 28 days)

Other outcomes

  1. Percent Change in DNA Methylation - Part I.

    Percent change in global DNA methylation in tumor and/or bronchial epithelium compared with pre-treatment.

    Time frame: Baseline (Day 1) to post-treatment. (Estimated minimum of 7 months)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — At the current time, there are no plans to show de-identified individual patient data but only aggregate data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2029, 30 months later.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 30 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2026
First posted
Oct 8, 2026
StartEst.
Jan 11, 2027
Primary completionEst.
Jul 13, 2029
CompletionEst.
Jul 12, 2030
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864584
Lead sponsor
Nob Hill Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 8, 2026
Start date
Jan 11, 2027 (estimated)
Primary completion
Jul 13, 2029 (estimated)
Completion
Jul 12, 2030 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion